Adaptive Biotechnologies Corp Quarterly Net Income (Loss) Attributable to Parent in USD from Q2 2018 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Adaptive Biotechnologies Corp quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q2 2018 to Q3 2024.
  • Adaptive Biotechnologies Corp Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$32.1M, a 36.2% increase year-over-year.
  • Adaptive Biotechnologies Corp Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$195M, a 0.36% increase year-over-year.
  • Adaptive Biotechnologies Corp annual Net Income (Loss) Attributable to Parent for 2023 was -$225M, a 12.5% decline from 2022.
  • Adaptive Biotechnologies Corp annual Net Income (Loss) Attributable to Parent for 2022 was -$200M, a 3.42% increase from 2021.
  • Adaptive Biotechnologies Corp annual Net Income (Loss) Attributable to Parent for 2021 was -$207M, a 41.8% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$195M -$32.1M +$18.2M +36.2% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 -$213M -$46.2M +$1.59M +3.32% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-01
Q1 2024 -$215M -$47.5M +$10.2M +17.7% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q4 2023 -$225M -$69.4M -$29.3M -73% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-29
Q3 2023 -$196M -$50.3M -$5.02M -11.1% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 -$191M -$47.8M +$4.24M +8.14% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-01
Q1 2023 -$195M -$57.7M +$5.04M +8.03% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 -$200M -$40.1M +$21.3M +34.7% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-29
Q3 2022 -$221M -$45.3M +$10.6M +19% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$232M -$52M -$2.75M -5.57% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-02
Q1 2022 -$229M -$62.7M -$22.1M -54.4% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-03
Q4 2021 -$207M -$61.4M -$16.9M -37.8% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-29
Q3 2021 -$190M -$55.9M -$19.2M -52.2% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 -$171M -$49.3M -$15.8M -47% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-03
Q1 2021 -$155M -$40.6M -$9.24M -29.4% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-04
Q4 2020 -$146M -$44.6M -$24M -116% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-14
Q3 2020 -$122M -$36.7M -$22.8M -163% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-03
Q2 2020 -$99.5M -$33.5M -$17.9M -114% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-04
Q1 2020 -$81.6M -$31.4M -$13M -70.8% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-05
Q4 2019 -$68.6M -$20.6M Oct 1, 2019 Dec 31, 2019 10-K 2022-02-15
Q3 2019 -$14M -$5.66M -68.2% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-10
Q2 2019 -$15.7M -$3.17M -25.3% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-10
Q1 2019 -$18.4M Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-12
Q3 2018 -$8.29M Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 -$12.5M Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.